ALS TDI Partners with Anida Pharma to Test Novel Therapy in ALS

The ALS Therapy Development Institute (ALS TDI) and Anida Pharma, Inc. have announced their formal collaboration to test Anida’s compound, Neuroprotectin D1 (NPD1), in SOD1 G93A mice to determine if there is “functional benefit.” ALS TDI has already tested NPD1 in a small proof-of-concept preclinical study and has shown that they can deliver NPD1 in “pharmacologically active levels” to the central nervous system of the mice. The encouraging proof-of-concept results supported investigation of NPD1 in an expanded preclinical study. NPD1 is thought to prevent neuronal death by reducing neuroinflammation as well as providing some trophic support.

The ALS Therapy Development Institute (ALS TDI) and Anida Pharma, Inc. have announced their formal collaboration to test Anida’s compound, Neuroprotectin D1 (NPD1), in SOD1 G93A mice to determine if there is “functional benefit.” ALS TDI has already tested NPD1 in a small proof-of-concept preclinical study and has shown that they can deliver NPD1 in “pharmacologically active levels” to the central nervous system of the mice. The encouraging proof-of-concept results supported investigation of NPD1 in an expanded preclinical study. NPD1 is thought to prevent neuronal death by reducing neuroinflammation as well as providing some trophic support.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail